Evidence map›Paper›PMID 31423878›Full record

ArticleCancer biology & therapy2019

Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.

Samuel Regan, Xuebin Yang, Niklas K Finnberg, Wafik S El-Deiry, Jeffrey J Pu

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Samuel ReganDepartment of Medicine, College of Medicine, SUNY Upstate Medical University , Syracuse , New York , USA.
Xuebin YangDepartment of Pathology, Perelman School of Medicine at the University of Pennsylvania , Philadelphia , PA , USA.
Niklas K FinnbergMedivir AB , Stockholm , Sweden.
Wafik S El-DeiryDepartment of Pathology, Warren Alpert Medical School, Brown University , Providence , Rhode Island , USA.
Jeffrey J PuDepartment of Medicine, College of Medicine, SUNY Upstate Medical University , Syracuse , New York , USA.ORCID 0000-0001-7498-3159
SUNY Upstate Medical University · USBrown University · USMedivir (Sweden) · SEUniversity of Pennsylvania · US

Funding

Research Training and Educational Component (Component I) p370-385P50DA036107 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI FOULDS, JONATHAN, MUSCAT, JOSHUA E · 2013 to 2018
$19.5M
NIDA NIH HHS P50 DA036107
6 · The paper itself

Abstract

Hydroxyurea (HU) has been widely used in sickle cell disease. Its potential long-term risk for carcinogenesis or leukemogenic risk remains undefined. Here, we report a 26 y old African-American female with Sickle Cell Disease (SCD) who developed refractory/relapsed acute myeloid leukemia (AML) 6 months after 26 months of HU use. That patient's cytogenetics and molecular genetics analyses demonstrated a complex mutation profile with 5q deletion, trisomy 8, and

Indexed as

AdultAnemia, Sickle CellCarcinogenesisChromosome DeletionChromosomes, Human, Pair 17Chromosomes, Human, Pair 5Chromosomes, Human, Pair 8FemaleHumansHydroxyureaLeukemia, Myeloid, AcuteMutationRisk FactorsHydroxyureaacute myeloid leukemia with myelodysplasia-related changesHydroxyureaP53 genesickle cell disease

Identifiers

PMID31423878
PMCPMC6804808
OpenAlexW2969752716

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.